Complete reference page for compounded tirzepatide in 2026: 503A vs 503B pathway, base vs salt-form distinction, pricing across telehealth providers, traceability standards, and clinical context.
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11
What is compounded tirzepatide?
Compounded tirzepatide is a customized preparation of the tirzepatide molecule prepared by a 503A licensed compounding pharmacy or a 503B FDA-registered outsourcing facility. It is dispensed in response to a patient-specific prescription (503A) or in batches (503B). It is not FDA-approved and is not the same product as Mounjaro® (FDA-approved for type 2 diabetes) or Zepbound® (FDA-approved for chronic weight management and obstructive sleep apnea), both manufactured by Eli Lilly.
Base vs salt forms (regulatory line)
The active pharmaceutical ingredient must be tirzepatide base. The FDA has issued warning letters specifically against compounded tirzepatide preparations using salt forms (tirzepatide acetate, tirzepatide sodium), citing that these are not pharmacologically equivalent to the base molecule. A legitimate compounded tirzepatide provider should be able to produce a certificate of analysis showing the active ingredient is tirzepatide base.
The 503A vs 503B pathway
503A: State-licensed compounding pharmacy. Prepares patient-specific medications under USP <797> sterile-compounding standards. Not FDA-inspected for product release. Beyond-use dates are typically shorter.
503B: FDA-registered outsourcing facility. Operates under cGMP (the same standard as commercial drug manufacturers). Can prepare batches in advance of patient-specific prescriptions. FDA-inspected.
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $147 (6-mo, save $108) · $149 (3-mo, save $48) · $165 (monthly).
Includes: medication, all MD/DO visits, messaging, lab review, personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Clinical context
Tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist. SURMOUNT-1 (NEJM 2022, PMID 35658024) demonstrated 20.9% mean weight loss at 15 mg / 72 weeks. SURMOUNT-OSA (NEJM 2024) demonstrated apnea-hypopnea index reduction in obesity-related OSA. The boxed warning is for thyroid C-cell tumors; contraindicated in personal/family history of MTC or MEN-2.
